FY2026 EPS Estimates for Pfizer Lifted by Erste Group Bank

Pfizer Inc. (NYSE:PFE) – Erste Group Bank upped their FY2026 earnings per share (EPS) estimates for Pfizer in a note issued to investors on Wednesday, August 5th. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will post earnings of $2.95 per share for the year, up from their prior forecast of $2.92. The consensus estimate for Pfizer’s current full-year earnings is $2.97 per share.

PFE has been the topic of a number of other reports. UBS Group reiterated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. CICC Research initiated coverage on shares of Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 target price on the stock. Guggenheim decreased their price target on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research report on Friday. Wolfe Research restated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $28.28.

Pfizer Price Performance

PFE opened at $26.61 on Wednesday. The stock’s 50-day moving average price is $25.07 and its 200 day moving average price is $26.18. Pfizer has a 12-month low of $23.58 and a 12-month high of $28.75. The firm has a market cap of $151.67 billion, a price-to-earnings ratio of 35.01 and a beta of 0.34. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the business posted $0.78 earnings per share. The company’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS.

Institutional Trading of Pfizer

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vermillion Wealth Management Inc. boosted its holdings in Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 382 shares during the last quarter. Eagle Capital Management LLC lifted its position in shares of Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after acquiring an additional 390 shares in the last quarter. Delta Financial Advisors LLC boosted its stake in shares of Pfizer by 1.6% in the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock worth $709,000 after acquiring an additional 398 shares during the last quarter. Pines Wealth Management LLC increased its position in shares of Pfizer by 4.4% during the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock worth $235,000 after purchasing an additional 400 shares in the last quarter. Finally, Mount Vernon Associates Inc. MD raised its stake in Pfizer by 1.0% in the 1st quarter. Mount Vernon Associates Inc. MD now owns 41,919 shares of the biopharmaceutical company’s stock valued at $1,177,000 after purchasing an additional 400 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. Pfizer’s payout ratio is presently 226.32%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Raised 2026 outlook and cost savings: Pfizer increased its 2026 guidance after reporting second-quarter earnings of $0.77 per share versus the $0.68 consensus estimate and revenue of $15.03 billion versus $14.40 billion expected. Non-COVID products grew 5%, while management is targeting approximately $9.7 billion in savings, supporting profitability. Pfizer Q2 2026 Earnings Call Transcript
• Positive Sentiment: Pipeline offers a potential growth replacement: Investor coverage is highlighting Pfizer’s expanding non-COVID pipeline and strategic efforts to reduce its dependence on pandemic products. A successful pipeline could help offset upcoming revenue losses. Pfizer’s Pipeline Could Change Everything
• Neutral Sentiment: Income appeal remains significant: Pfizer’s roughly 6.4% dividend yield is well above the S&P 500 average, making PFE attractive to income-focused investors, although the high payout also reflects concerns about earnings quality and future growth. Pfizer vs AbbVie: What’s the Better Dividend Stock
• Negative Sentiment: Guidance increase may be less durable: Analysts noted that much of the improved 2026 outlook relies on a drug approaching patent expiry. That creates a potential revenue cliff from generic competition, though Pfizer says it is implementing measures to address the risk. Pfizer Raised 2026 Guidance
• Negative Sentiment: Dividend-cut concerns persist: Pfizer’s earnings have reportedly declined sharply this year, raising questions about whether its elevated dividend is sustainable if cash flow and earnings remain under pressure. Pfizer Earnings and Dividend Cut Concerns
• Negative Sentiment: Legal liability adds a financial overhang: Pfizer agreed to a $44 million settlement related to Chantix, creating a modest near-term cost and additional headline risk. Pfizer Chantix Settlement

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.